[go: up one dir, main page]

Sun et al., 2008 - Google Patents

Chaperone displacement from mutant cystic fibrosis transmembrane conductance regulator restores its function in human airway epithelia

Sun et al., 2008

View HTML @Full View
Document ID
6011612432409224284
Author
Sun F
Mi Z
Condliffe S
Bertrand C
Gong X
Lu X
Zhang R
Latoche J
Pilewski J
Robbins P
Frizzell R
Publication year
Publication venue
The FASEB Journal

External Links

Snippet

Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause cystic fibrosis (CF). The most common mutation, ΔF508, omits the phenylalanine residue at position 508 in the first nucleotide binding domain (NBD1) of CFTR. The mutant protein is …
Continue reading at pmc.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Similar Documents

Publication Publication Date Title
Sun et al. Chaperone displacement from mutant cystic fibrosis transmembrane conductance regulator restores its function in human airway epithelia
Yin et al. CDK4/6 regulate lysosome biogenesis through TFEB/TFE3
Liao et al. The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1
Joch et al. Parkin-mediated monoubiquitination of the PDZ protein PICK1 regulates the activity of acid-sensing ion channels
Zhemkov et al. The role of sigma 1 receptor in organization of endoplasmic reticulum signaling microdomains
Gao et al. Heat shock protein 70 together with its co-chaperone CHIP inhibits TNF-α induced apoptosis by promoting proteasomal degradation of apoptosis signal-regulating kinase1
US9226952B2 (en) Na/K-ATPase-derived peptide Src inhibitors and ouabain antagonists and uses thereof
Sung et al. Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53
Lu et al. Golgi-associated RhoBTB3 targets cyclin E for ubiquitylation and promotes cell cycle progression
Vincent et al. Constitutive Cdc25B tyrosine phosphatase activity in adult brain neurons with M phase-type alterations in Alzheimer’s disease
Hoshino et al. Molecular chaperone GRP94 binds to the Fanconi anemia group C protein and regulates its intracellular expression
Chatelain et al. Molecular dissection reveals decreased activity and not dominant negative effect in human OTX2 mutants
Huang et al. Acetylation within the N-and C-terminal domains of Src regulates distinct roles of STAT3-mediated tumorigenesis
Huot et al. An adaptor role for cytoplasmic Sam68 in modulating Src activity during cell polarization
Baron et al. Characterization of drug-induced human mitochondrial ADP/ATP carrier inhibition
Zhao et al. The lim domain protein fhl1c interacts with tight junction protein zo-1 contributing to the epithelial–mesenchymal transition (emt) of a breast adenocarcinoma cell line
Maita et al. Association of PAP-1 and Prp3p, the products of causative genes of dominant retinitis pigmentosa, in the tri-snRNP complex
Mattagajasingh et al. Activation of Stat3 in endothelial cells following hypoxia–reoxygenation is mediated by Rac1 and protein kinase C
Yamada et al. Trans-membrane peptide therapy for malignant glioma by use of a peptide derived from the MDM2 binding site of p53
Jaberi et al. Identification of Tpr and α-actinin-4 as two novel SLK-interacting proteins
US7364870B2 (en) MK2 interacting proteins
Węsierska-Gądek Targeting p53 as a promising therapeutic option for cancer by re-activating the wt or mutant p53’s tumor suppression
Segura-Roman et al. Autophagosomes coordinate an AKAP11-dependent regulatory checkpoint that shapes neuronal PKA signaling
Treharne et al. Protein kinase CK2, cystic fibrosis transmembrane conductance regulator, and the ΔF508 mutation: F508 deletion disrupts a kinase-binding site
Chen et al. Sequence and structural variations determining the recruitment of WNK kinases to the KLHL3 E3 ligase